DNA vaccination for HIV-1 and SIV

Intervirology

Volumn 43, Issue 4-6, 2000, Pages 282-287

  Barouch, Dan H ^a   Letvin, Norman L ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

DNA vaccine; HIV 1; Immunization, genetic; SIV

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELLULAR IMMUNITY; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

AIDS VACCINES; ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, DNA;

AIDS VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0034468242     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053995     Document Type: Article

References (60)

1. HIV/AIDS in 1998 -Gaining the upper hand?
2. Progress in the development of an HIV-1 vaccine
3. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
4. Virus-specific CD8+ cytolytic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
5. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV
6. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
7. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
8. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
9. Simian immunodeficiency virus specific CD8+ lymphocyte response in acutely infected rhesus monkeys
10. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficency virus of macaques
11. T cell receptor Vβ repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus
12. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
13. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques
14. Direct gene transfer into mouse muscle in vivo
15. Genetic immunization is a simple method for eliciting an immune response
16. DNA vaccines
17. DNA vaccines
18. Genetic immunization: A new era in vaccines and immune therapies
19. Heterologous protection against influenza by injection of DNA encoding a viral protein
20. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type-1 in mice and nonhuman primates
21. Gene inoculation generates immune responses against human im-munodecifiency virus type 1
22. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice
23. Induction of humoral and cellular immune responses to the human immunodeficiency virus type 1 in non-human primates
24. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination
25. Humoral and cellular immunities elicited by HIV-1 DNA vaccination
26. Vaccination of mice and nonhuman primates using HIV gene-containing DNA
27. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-γ and TNF-α
28. Anti-HIV env immunities elicited by nucleic acid vaccines
29. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus macaques
30. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
31. DNA vaccination for HIV
32. Simian immunodeficiency virus DNA vaccine trial in macaques
33. Protection from pathogenic SIV challenge using multigenic DNA vaccines
34. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
35. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
36. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial
37. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
38. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts
39. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
40. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regimen
41. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
42. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen
43. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV
44. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
45. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
46. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines
47. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
48. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
49. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1
50. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
51. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens
52. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
53. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
54. Development of a multicomponent candidate vaccine for HIV-1
55. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes
56. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo
57. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines
58. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity
59. Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances DNA vaccine-induced immune response against HIV-1
60. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration